САТХИАНАРАЯНАН Срирам (US),КАСИБХАТЛА Схайладжа (US),ВИНТЕР Кристофер (US),ЧАСТАЙН Майкл (US)
申请号：
RU2011146339/15
公开号：
RU2011146339A
申请日:
2010.04.06
申请国别(地区):
RU
年份:
2013
代理人:
摘要：
1. A method of treating or preventing a disease in a subject, comprising administering to the subject a therapeutically effective amount of a combination of therapeutic agents, including a tyrosine kinase inhibitor and an IGF-1R inhibitor, or a pharmaceutical composition thereof, the administration of a combination of therapeutic agents leading to increased therapeutic efficacy compared to administration alone an EGFR inhibitor or an IGF-1R inhibitor sufficient to treat a specified patient. 2. The method of claim 1, wherein the tyrosine kinase inhibitor is Erlotinib. The method of claim 1, wherein said disease is Erlotinib-resistant cancer. The method according to claim 1, wherein said IGF-1R inhibitor or one of its functional fragments is an antibody that specifically binds to human IGF-1R and includes at least one complementarity determining region (CDR) of the heavy chain derived from a non-human a source, and at least one complementarity determining region (CDR) of the light chain originating from a non-human source, said antibody that binds to IGF-1R having at least one of the following properties, you iraemym from the group consisting of a) binding to IGF-1R, but not with the IR； (b) binding to a hybrid receptor including an insulin receptor and an insulin-like growth factor receptor (hybrid R-IR / IGF-1R), but not with IR itself； (c) inhibition of binding between human IGF-1R and IGF-1 and / or IGF-2； (d) inhibition of binding between hybrid R and its natural ligand, which is generally referred to here as IGF-1 and / or IGF-2, and / or insulin, with an inhibitory constant1. Способ лечения или предупреждения заболевания у субъекта, включающий введение указанному субъекту терапевтически эффективного количества комбинации терапевтических средств, включающей ингибитор тирозинкиназ и ингибитор IGF-1R, или их фармацевтической композиции, причем введение комбинации терапевтических средств приводит к увеличенной терапевтической эффективности по сравнению с введением
